We're sorry you missed the webinar. You can still see a recording by filling out the form below.Gain Access
This site uses features not supported by Internet Explorer.
The weight loss drug Belviq (lorcaserin) was initially approved by the FDA in 2012 as an add-on treatment for obesity and in those experiencing obesity-related health issues. The medication worked by controlling the appetite by activating brain receptors for serotonin to trigger feelings of fullness. During a review of clinical safety trials, the FDA found an increased occurrence of cancers in subjects who took Belviq compared to the placebo group. There may also be risk of other injuries.
It appears the manufacturers may have deceived the FDA, knew or should have known about the link between Belviq and cancer for years but withheld the information from consumers, regulators and the medical community.